In adults with type 2 diabetes on metformin, the chronic eGFR slope with liraglutide (-2.08 mL/min/1.73 m2 per year) did not differ significantly from sitagliptin, glimepiride or insulin glargine (P = .61).
In plain wordsIn adults with type 2 diabetes, kidney function declined at a similar rate on liraglutide as on sitagliptin, glimepiride or insulin glargine.
- Peptide
- Liraglutide
- Outcome
- No significant changeChronic eGFR slope
- Study
n = 5,047
- Comparator
- Sitagliptin, glimepiride, insulin glargine (each added to metformin)
- Analysis
- Primary
- Outcome group
- Kidney function · Kidney and urinary
- Studied dose
- Dose not stated · mean follow-up 5.0 yearsAs given in this study (human).
Measurements
- Chronic eGFR slope
- −2.08 mL/min/1.73 m2 per year
- liraglutide
Source sentences
Mean chronic eGFR slope was -2.03 (95% CI, -2.20 to -1.86) mL/min/1.73 m2 per year for patients receiving sitagliptin; glimepiride, -1.92 (95% CI, -2.08 to -1.75) mL/min/1.73 m2 per year; liraglutide, -2.08 (95% CI, -2.26 to -1.90) mL/min/1.73 m2 per year; and insulin glargine, -2.02 (95% CI, -2.19…
2 context sentences(design, population, supporting numbers)
Participants included adults with T2D for less than 10 years, a hemoglobin A1c level between 6.8% and 8.5%, and estimated glomerular filtration rate (eGFR) greater than or equal to 60 mL/min/1.73 m2 who were receiving metformin treatment.
Addition of insulin glargine, glimepiride, liraglutide, or sitagliptin to metformin, with the medication combination continued until the HbA1c was greater than 7.5%; thereafter, insulin was added to maintain glycemic control.